Biotechnology News and Research RSS Feed - Biotechnology News and Research

Biogen Idec's revenue increases 51% to $2.1 billion in first quarter 2014

Biogen Idec's revenue increases 51% to $2.1 billion in first quarter 2014

Biogen Idec Inc. today reported first quarter 2014 results, including revenue of $2.1 billion, a 51% increase compared to the first quarter of 2013. [More]
WLSA's Convergence Summit to focus on global adoption of technology-enabled health care

WLSA's Convergence Summit to focus on global adoption of technology-enabled health care

The Wireless-Life Sciences Alliance said today that its ninth annual Convergence Summit here next month will focus on achieving broader global adoption of technology-enabled health care at a time when the pace of innovation in connected health and personal health solutions is accelerating. [More]
Captisol-enabled Melphalan meets primary end points in phase 2 pivotal trial

Captisol-enabled Melphalan meets primary end points in phase 2 pivotal trial

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that its pivotal trial of Captisol-enabled (propylene glycol-free) Melphalan met its primary end points. [More]
HemoShear announces research collaboration with Medivir

HemoShear announces research collaboration with Medivir

HemoShear, LLC, the human disease biology company, today announced research collaboration with Medivir AB of Stockholm, Sweden, an emerging research-based pharmaceutical company focused on infectious diseases. [More]
Alexion Pharmaceuticals obtains orphan drug designation from EC for Soliris

Alexion Pharmaceuticals obtains orphan drug designation from EC for Soliris

Alexion Pharmaceuticals, Inc. today announced that the European Commission has granted an orphan drug designation (ODD) to Soliris (eculizumab), a first-in-class terminal complement inhibitor, for the prevention of graft rejection following solid organ transplantation. Graft rejection can cause severe injury to the transplanted organ and is a significant barrier to successful transplantation. [More]
Interleukin receives conditional approval to offer results of PerioPredict genetic risk test

Interleukin receives conditional approval to offer results of PerioPredict genetic risk test

Interleukin Genetics, Inc. today announced it has received conditional approval from the New York State Department of Health to offer, process and report the results of the PerioPredict™ Genetic Risk Test for periodontal disease. [More]
Can-Fite BioPharma signs agreement with Smart Assays to develop A3AR predictive biomarker kit

Can-Fite BioPharma signs agreement with Smart Assays to develop A3AR predictive biomarker kit

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today it has signed an agreement with Smart Assays to develop a commercial biomarker blood test kit for the A3 adenosine receptor (A3AR). [More]
Genmab/GSK receive FDA sBLA approval for Arzerra in combination with chlorambucil for treatment of CLL

Genmab/GSK receive FDA sBLA approval for Arzerra in combination with chlorambucil for treatment of CLL

GlaxoSmithKline plc and Genmab A/S announced today that the U.S. Food and Drug Administration (FDA) has approved a Supplemental Biologic License Application (sBLA) for the use of Arzerra® (ofatumumab), a CD20-directed cytolytic monoclonal antibody, in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukaemia (CLL) for whom fludarabine-based therapy is considered inappropriate. [More]

New computational method speeds up estimates of gene activity from RNA-seq data

With gene expression analysis growing in importance for both basic researchers and medical practitioners, researchers at Carnegie Mellon University and the University of Maryland have developed a new computational method that dramatically speeds up estimates of gene activity from RNA sequencing (RNA-seq) data. [More]

Cyclenium Pharma signs drug discovery and development agreement with Southern Research Institute

Cyclenium Pharma Inc., an emerging pharmaceutical company specializing in the research and development of novel drug candidates based on proprietary macrocyclic chemistry, today announced the signing of a discovery and co-development agreement with Southern Research Institute, a not-for-profit 501(c)(3) scientific research organization founded in 1941. [More]

Research report on flow cytometry market

According to the new market research report "Flow Cytometry Market by Technology (Cell & Bead-based), Products & Services (Reagents, Instruments, Software, & Accessories), Application (Research & Clinical), End User (Commercial Organizations & Diagnostics Laboratories) - Global Forecasts to 2018", analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Europe, Asia-Pacific, and Rest of the world (RoW). [More]
Researchers discover new marker derived from human umbilical cord blood

Researchers discover new marker derived from human umbilical cord blood

The development of stem cell therapies to cure a variety of diseases depends on the ability to characterize stem cell populations based on cell surface markers. [More]
Concise analysis of global bioactive ingredients market

Concise analysis of global bioactive ingredients market

The report "Bioactive Ingredients & Product Market by Ingredient (Probiotics, Proteins, Plant Extracts, Minerals, Vitamins, Fibers, Carotenoids), by Product (Functional Foods, & Beverage, Dietary Supplements, Animal Nutrition, Personal Care) - Global trends & forecast to 2018", is published by MarketsandMarkets. [More]

13th annual Bio-IT World Conference & Expo to launch new disciplinary track on data security

The 13th annual Bio-IT World Conference & Expo, to be held April 29-May 1 at the Seaport World Trade Center in Boston, today announced that it will debut a new disciplinary track focused on data security. [More]

Food shortage will have serious implications for people and governments in the world

The world is less than 40 years away from a food shortage that will have serious implications for people and governments, according to a top scientist at the U.S. Agency for International Development. [More]
Targeted Medical Pharma signs agreement with Lebanon based company, ATL

Targeted Medical Pharma signs agreement with Lebanon based company, ATL

Targeted Medical Pharma, today announced the completion of an agreement between Analytical Testing Laboratories (ATL), a Lebanon based company that specializes in drug testing services and inborn errors of metabolism, for the exclusive distribution of the company's amino acid based products to physicians and pharmacies throughout the Middle East. [More]

Nora Therapeutics closes $18M Series B financing to expand drug development

Nora Therapeutics, a biotechnology company focused on developing therapeutics to address unmet needs in reproductive medicine, today announced the closing of an $18 million Series B financing. [More]
Researchers develop class of drugs to lessen impact of Alzheimer's, Parkinson's

Researchers develop class of drugs to lessen impact of Alzheimer's, Parkinson's

​A class of drugs developed to treat immune-related conditions and cancer - including one currently in clinical trials for glioblastoma and other tumors - eliminates neural inflammation associated with dementia-linked diseases and brain injuries, according to UC Irvine researchers. [More]
Iconic Therapeutics completes $20 million Series B-1 equity financing

Iconic Therapeutics completes $20 million Series B-1 equity financing

Iconic Therapeutics, Inc., a biotechnology company focused on developing therapeutics for serious eye disorders, announced today that it has successfully completed a $20 million Series B-1 equity financing from new investors MPM Capital, Lundbeckfond Ventures, and H.I.G. BioVentures. [More]

Baxter reports topline results from BAX 111 Phase 3 trial for treatment of von Willebrand disease

Baxter International Inc. today announced topline results from a Phase 3 clinical trial evaluating the safety, efficacy and pharmacokinetics (PK) of BAX 111. BAX 111 is a recombinant von Willebrand factor (rVWF) under investigation for the treatment of bleeding episodes in patients with von Willebrand disease, the most common type of inherited bleeding disorder. [More]